Aggressive statin therapy for acute coronary syndromes
Purchase on Springer.com
$39.95 / €34.95 / £29.95*
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.
Acute coronary syndromes (ACS) account for an enormous disease burden, especially in the Western world. Patients suffering acute coronary events are now understood to carry a very high risk of further coronary events and although improvements in conventional medical therapy over the past two decades have significantly reduced the risk, it remains high. Therapy with HMG CoA reductase inhibitors (statins) have now been well established for the primary and secondary prevention of stable coronary heart disease, but recently a substantial body of evidence has proven their efficacy in the treatment of ACS. This article examines this emerging evidence for the use of statins in ACS.
- Naghavi M, Libby P, Falk E, Casscells SW, et al.:From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: part I.Circulation 2003,108:1664–1672. CrossRef
- Naghavi M, Libby P, Falk E, et al.:From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: part II.Circulation 2003,108:1772–1778. CrossRef
- Wallentin L, Lagerqvist B, Husted S, et al.:Outcome at 1 year after an invasive compared with a non-invasive strategy in unstable coronary-artery disease: the FRISC II invasive randomised trial. FRISC II Investigators. Fast Revascularisation during Instability in Coronary artery disease.Lancet 2000,356:9–16. CrossRef
- Rosamond W, Flegal K, Friday G, et al.:Heart disease and stroke statistics-2007 update. A report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee, for the American Heart Association Statistics Committee and Stroke Statistics Subcommittee.Circulation 2007,115:e69-e171. CrossRef
- Hospital Episode Statistics 2004–2005. Available at http://www.hesonline.nhs.uk/. Accessed April 24, 2007.
- Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S).Lancet 1994,344:1383–1389.
- Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group.N Engl J Med 1998,339:1349–1357.
- Sacks FM, Pfeffer MA, Moye LA, et al.:The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators.N Engl J Med 1996,335:1001–1009. CrossRef
- Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS).Circulation 1998,97:1440–1445.
- Sever PS, Dahlof B, Poulter NR, et al.:Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial.Lancet 2003,361:1149–1158. CrossRef
- Collins R, Armitage J, Parish S, et al.:MRC/BHF Heart Protection Study of Cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo controlled trial.Lancet 2002,360:7–22. CrossRef
- Of major importance Baigent C, Keech A, Kearney PM, et al.:Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins.Lancet 2005,366:1267–1278. An important meta-analysis demonstrating the benefit of statins in all patients with CHD or those at high risk. CrossRef
- Of importance Spencer FA, Allegrone J, Goldberg AJ, et al.:Association of statin therapy with outcomes of acute coronary syndromes: the GRACE study.Ann Intern Med 2004,140:857–866. A large observational study showing the benefit of statin therapy following ACS and the early loss of protection on statin withdrawal.
- Of importance Fonarow GC, Wright RS, Spencer FA, et al.:Effect of statin use within the first 24 hours of admission for acute myocardial infarction on early morbidity and mortality.Am J Cardiol 2005,96:611–616. A large observational study showing the benefit of statin therapy following ACS and the early loss of protection on statin withdrawal. CrossRef
- Liem AH, van Boven AJ, Veeger NJ, et al.:Effect of fluvastatin on ischaemia following acute myocardial infarction: a randomized trial.Eur Heart J 2002,23:1931–1937. CrossRef
- Ostadal P, Alan D, Hajek P, et al.:Fluvastatin in the therapy of acute coronary syndrome: rationale and design of a multicenter, randomized, double-blind, placebo-controlled trial (The FACS Trial)[ISRCTN81331696].Curr Control Trials Cardiovasc Med 2005,6:4. CrossRef
- Thompson PL, Meredith I, Amerena J, et al.:Effect of pravastatin compared with placebo initiated within 24 hours of onset of acute myocardial infarction or unstable angina: the Pravastatin in Acute Coronary Treatment (PACT) trial.Am Heart J 2004,148:e2. CrossRef
- Of major importance de Lemos JA, Blazing MA, Wiviott SD, et al.:Early intensive vs a delayed conservative simvastatin strategy in patientsw with acute coronary syndromes: phase Z of the A to Z trial.JAMA 2004,292:1307–1316. Important trial showing the limited effects of a moderate statin therapy. CrossRef
- Schwartz GG, Olsson AG, Ezekowitz MD, et al.:Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial.JAMA 2001,285:1711–1718. CrossRef
- Of major importance Olsson AG, Schwartz GG, Szarek M, et al.:High-density lipoprotein, but not low-density lipoprotein cholesterol levels influence short-term prognosis after acute coronary syndrome: results from the MIRACL trial.Eur Heart J 2005,26:890–896. An important study demonstrating that early risk reduction is not related to LDL cholesterol-reducing mechanisms. CrossRef
- Waters DD, Schwartz GG, Olsson AG, et al.:Effects of atorvastatin on stroke in patients with unstable angina or non-Q-wave myocardial infarction: a Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) substudy.Circulation 2002,106:1690–1695. CrossRef
- Pedersen TR, Kjekshus J, Pyorala K, et al.:Effect of simvastatin on ischemic signs and symptoms in the Scandinavian simvastatin survival study (4S).Am J Cardiol 1998,81:333–335. CrossRef
- Plehn JF, Davis BR, Sacks FM, et al.:Reduction of stroke incidence after myocardial infarction with pravastatin: the Cholesterol and Recurrent Events (CARE) study. The Care Investigators.Circulation 1999,99:216–223.
- White HD, Simes RJ, Anderson NE, et al.:Pravastatin therapy and the risk of stroke.N Engl J Med 2000,343:317–326. CrossRef
- Of major importance Cannon CP, Braunwald E, McCabe CH, et al.:Intensive versus moderate lipid lowering with statins after acute coronary syndromes.N Engl J Med 2004,350:1495–1504. A landmark trial demonstrating for the first time the early benefits of an aggressive statin therapy against a moderate statin therapy in terms of clinical outcomes. CrossRef
- Of major importance Ray KK, Cannon CP, McCabe CH, et al.:Early and late benefits of high-dose atorvastatin in patients with acute coronary syndromes: results from the PROVE IT-TIMI 22 trial.J Am Coll Cardiol 2005,46:1405–1410. This study demonstrates that aggressive statin therapy can have statistically significant benefits as early as 30 days post-event. CrossRef
- Buchwald H, Varco RL, Matts JP, et al.:Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia. Report of the Program on the Surgical Control of the Hyperlipidemias (POSCH).N Engl J Med 1990,323:946–955.
- Buchwald H, Varco R L, Boen JR, et al.: for the POSCH Group:Effective lipid modification by partial ileal bypass reduced long-term coronary heart disease mortality and morbidity: five-year post-trial follow-up report from the POSCH.Arch Intern Med 1998,158:1253–1261. CrossRef
- Of major importance Ray KK, Cannon CP:The potential relevance of the multiple lipid-independent (pleiotropic) effects of statins in themanagement of acute coronary syndromes.J Am Coll Cardiol 2005,46:1425–1433. A comprehensive review of the potential pleiotropic effects of statins. CrossRef
- Kinlay S, Schwartz GG, Olsson AG, et al.:High-dose atorvastatin enhances the decline in inflammatory markers in patients with acute coronary syndromes in the MIRACL study.Circulation 2003,108:1560–1566. CrossRef
- Of importance Kinlay S, Schwartz GG, Olsson AG, et al.:Effect of atorvastatin on risk of recurrent cardiovascular events after an acute coronary syndrome associated with high soluble CD40 ligand in the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study.Circulation 2004,110:386–391. This demonstrates that high-dose statins abrogate the higher coronary risk associated with high CD40L levels. CrossRef
- Of major importance Ridker PM, Cannon CP, Morrow D, et al.:C-reactive protein levels and outcomes after statin therapy.N Engl J Med 2005,352:20–28. A landmark study showing that low CRP levels predict a lower longterm coronary event rate independent of LDL cholesterol levels. CrossRef
- Of importance Wiviott SD, de Lemos JA, Cannon CP, et al.:A tale of two trials: a comparison of the post-acute coronary syndrome lipid-lowering trials A to Z and PROVE IT-TIMI 22.Circulation 2006,113:1406–1414. This study highlights the importance of inflammation reduction in the difference in efficacy between intensive and moderate statin therapies. CrossRef
- Of major importance Ridker PM, Morrow DA, Rose LM, et al.:Relative efficacy of atorvastatin 80 mg and pravastatin 40 mg in achieving the dual goals of low-density lipoprotein cholesterol <70 mg/dl and C-reactive protein <2 mg/l: an analysis of the PROVE-IT TIMI-22 trial.J Am Coll Cardiol 2005,45:1644–1648. This paper highlights the importance of dual LDL cholesterol and CRP reduction goals and demonstrates the difference between intensive and moderate statin therapies in achieving these goals. CrossRef
- Of major importance Wiviott SD, Cannon CP, Morrow DA, et al.:Can lowdensity lipoprotein be too low? The safety and efficacy of achieving very low low-density lipoprotein with intensive statin therapy: a PROVE IT-TIMI 22 substudy.J Am Coll Cardiol 2005,46:1411–1416. This analysis demonstrates that ultra low levels of LDL cholesterol are safe and associated with increased efficacy and therefore statin dose should not be down-titrated among subjects with ultra low LDL cholesterol levels. CrossRef
- Of major importance Ray KK, Cannon CP, Cairns R, et al.:Relationship between uncontrolled risk factors and C-reactive protein levels in patients receiving standard or intensive statin therapy for acute coronary syndromes in the PROVE IT-TIMI 22 trial.J Am Coll Cardiol 2005,46:1417–1424. An important analysis highlighting the link between risk factors, statins, and inflammation, showing that risk factor reduction can reduce inflammation and that CRP can monitor this effect. CrossRef
- Aggressive statin therapy for acute coronary syndromes
Current Cardiology Reports
Volume 9, Issue 4 , pp 298-302
- Cover Date
- Print ISSN
- Online ISSN
- Additional Links